Effects of the Cholinesterase Inhibitor Donepezil on Organic and Functional Deficits Associated With Age-Related Decrease of Growth Hormone

Ludwig Boltzmann Gesellschaft1 site in 1 country80 target enrollmentSeptember 2007

ConditionsElderly

Overview

The planned study has two purposes:

It is to provide evidence that the administration of a cholinesterase inhibitor will result in an increase of IGF-I (primary variable) and in an increase of the secretion growth hormone (secondary variable) that can be maintained throughout the treatment-period of one year.
The study also tests the hypothesis that maintenance of increased blood levels of growth hormone and IGF-I can stop or delay the age-related changes of body composition (secondary variables) .

Registry

clinicaltrials.gov

Start Date

September 2007

End Date

July 2009

Last Updated

16 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Sponsor

•Cardiac arrhythmias (sick sinus syndrome, AV block, sino-atrial block),
•Treatment with beta-blockers, NSAIDs or cholinergic agonists,
•Known hypersensitivity to donepezil hydrochloride, piperidine derivatives or to any excipients used in the formulation,
•Gastric and duodenal ulcer,
•Severe renal and hepatic impairment,
•Urinary congestion (prostatic hypertrophy),
•Obstructive pulmonary disease (bronchial asthma);